# Susanne SauÃele

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7351781/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 35 papers | 3,422 citations | 430874 18 h-index | 395702 33 g-index |
| 35 all docs | 35 docs citations | 35 times ranked | 3217 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia, 2022, 36, 1834-1842. | 7.2 | 10 |
| 2 | Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases. Annals of Hematology, 2022, 101, 1825-1834. | 1.8 | 7 |
| 3 | Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response. Hematologic Malignancies, 2021, , 265-273. | 0.2 | 0 |
| 4 | Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMRâ€"final report from AFTER-SKI. Leukemia, 2021, 35, 2416-2418. | 7.2 | 13 |
| 5 | Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia, 2021, 35, 1344-1355. | 7.2 | 43 |
| 6 | A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 2021, 138, 2031-2041. | 1.4 | 147 |
| 7 | Chronic myeloid leukaemia. Lancet, The, 2021, 398, 1914-1926. | 13.7 | 65 |
| 8 | Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response. Blood, 2021, 138, 3608-3608. | 1.4 | 3 |
| 9 | FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study. Blood, 2021, 138, 633-633. | 1.4 | 10 |
| 10 | Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. Blood, 2021, 138, 1476-1476. | 1.4 | 1 |
| 11 | The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis. Haematologica, 2020, 105, 136-147. | 3.5 | 44 |
| 12 | Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematologica, 2020, 143, 217-231. | 1.4 | 26 |
| 13 | Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia, 2020, 34, 2113-2124. | 7.2 | 22 |
| 14 | Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia, 2020, 34, 2125-2137. | 7.2 | 47 |
| 15 | DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia. International Journal of Molecular Sciences, 2020, 21, 1177. | 4.1 | 20 |
| 16 | Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients. Annals of Hematology, 2020, 99, 991-1006. | 1.8 | 3 |
| 17 | Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in | | |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. PLoS ONE, 2019, 14, e0214305. | 2.5 | 16 |
| 20 | Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia. Blood, 2019, 134, 1647-1647. | 1.4 | 3 |
| 21 | Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. Journal of Cancer Research and Clinical Oncology, 2018, 144, 945-954. | 2.5 | 124 |
| 22 | Effect of ABCG2 , OCT1 , and ABCB1 ( MDR1 ) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 266-271. | 0.4 | 18 |
| 23 | Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia, 2018, 32, 1222-1228. | 7.2 | 22 |
| 24 | Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncology, The, 2018, 19, 747-757. | 10.7 | 444 |
| 25 | Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. Cancer Research, 2018, 78, 6223-6234. | 0.9 | 16 |
| 26 | The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia. PLoS ONE, 2018, 13, e0196326. | 2.5 | 7 |
| 27 | Management of CML-blast crisis. Best Practice and Research in Clinical Haematology, 2016, 29, 295-307. | 1.7 | 60 |
| 28 | Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?. Journal of Clinical Oncology, 2014, 32, 2821-2823. | 1.6 | 122 |
| 29 | Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology, 2014, 32, 415-423. | 1.6 | 271 |
| 30 | Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Annals of Hematology, 2014, 93, 71-80. | 1.8 | 60 |
| 31 | Older patients with chronic myeloid leukemia (â‰¥65Âyears) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Annals of Hematology, 2014, 93, 1167-1176. | 1.8 | 21 |
| 32 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884. | 1.4 | 1,743 |
| 33 | Clinical Trials in Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports, 2012, 7, 109-115. | 2.3 | 3 |
| 34 | Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV. Blood, 2008, 112, 184-184. | 1.4 | 8 |
| 35 | Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV. Blood, 2008, 112, 448-448. | 1.4 | 3 |